COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Population Pharmacokinetics of Anti-infectious Drugs in Children (PHARMA-A)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01344512
Recruitment Status : Completed
First Posted : April 29, 2011
Last Update Posted : March 18, 2015
Information provided by (Responsible Party):
University Hospital, Bordeaux

Brief Summary:
The Pharm A project is a French national collaborative project aiming to determine the population pharmacokinetics of ceftazidime, ciprofloxacin, and voriconazole in paediatric patients aged one month to five years.

Condition or disease Intervention/treatment Phase
Pediatrics Ceftazidime Ciprofloxacin Voriconazole Drug: Ceftazidime Drug: Ciprofloxacin Drug: Voriconazole Not Applicable

Detailed Description:

The licensing process was introduced in order to ensure that medicines are safe, effective and of high quality. However, over 50% of children admitted to hospital in France and Europe will receive an unlicensed or off-label medicine. This occurs for most drugs in children less than 6 years of age. They represent a particularly vulnerable subgroup of the paediatric population.

There are major practical and ethical issues in relation to studying medicines in paediatric patients aged 5 years or less.

  • They represent only a small part of the population as compared to older children and adults, and the variation of specific types of diseases in this young subpopulation is higher than in the paediatric counterpart. There are major differences in drug disposition in the different age groups.
  • There is a need for suitable methodological approaches for clinical trials
  • There are major ethical issues It is essential, therefore, to recruit children from various regions in France in order to obtain a critical sample size of sufficient magnitude and to conduct scientific sound studies. This will be achieved by performing Pharm A, a population pharmacokinetic study of three different anti infectious agents (ceftazidime, ciprofloxacin, voriconazole) and identify covariates including pharmacogenetic biomarkers that explain pharmacokinetic variability.

After parental informed consent, sampling strategy will be randomized depending on the drug and the age group (2 samples in patients below 2 years and 3 samples in patients from 2 to 5 years).

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 214 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Population Pharmacokinetics Of Ceftazidime, Ciprofloxacin And Voriconazole In Paediatric Young Patients (< 12 Years Old)
Study Start Date : June 2011
Actual Primary Completion Date : September 2014
Actual Study Completion Date : September 2014

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Patients treated with Ceftazidime Drug: Ceftazidime
Bloods sampling on patient treated with Ceftazidime between 48 hours and 4 days after beginning of treatment.

Experimental: Patients treated with Ciprofloxacin Drug: Ciprofloxacin
Bloods sampling on patient treated with Ciprofloxacin between 48 hours and 4 days after beginning of treatment.

Experimental: Patients treated with Voriconazole Drug: Voriconazole
Bloods sampling on patient treated with Voriconazole between 48 hours and 4 days after beginning of treatment.

Primary Outcome Measures :
  1. Population pharmacokinetic parameters and factors explaining variability [ Time Frame: Between 2 and 4 days after the begining of the treatment ]

    Population Pharmacokinetic Parameters and variability factors (Sex, Age, Genetic factors...) for ceftazidime, ciprofloxacin and voriconazole.

    According to the age of participants, 2 or 3 bloods sampling will be take between 2 and 4 days after the beginning of the treatment.

Secondary Outcome Measures :
  1. Covariability factors explaining the variability (age, biological data, pharmacokinetics factors, associated treatments...) [ Time Frame: Between 2 and 4 days after the beginning of the treatment ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   up to 6 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Children aged 28 days to 11 years (< 12 years)
  • Receiving one of the following drugs for therapeutic reasons : ceftazidime, ciprofloxacin, voriconazole
  • Representative for the clinician, a condition requiring the use of these molecules
  • Informed consent signed by the two parents or legal representative
  • Child affiliated to the national social security system

Exclusion Criteria:

Not Applicable

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01344512

Layout table for location information
CHU de Bordeaux, Hôpital Pellegrin
Bordeaux, France, 33076
Hospices Civils de Lyon
Bron, France, 69500
CHU Clermont Ferrand
Clermont Ferrand, France, 63000
CHU de Dijon
Dijon, France, 21079
CHU de Grenoble
Grenoble, France, 38043
CHRU Lille
Lille, France, 59037
AP-HM, Hôpital La Timone
Marseille, France, 13005
CHU Montpellier
Montpellier, France, 34925
APHP - Hôpital NEcker
Paris, France, 75015
AP-HP - Hôpital Robert Debré
Paris, France, 75019
CHU Poitiers
Poitiers, France, 86000
CHU Rouen
Rouen, France, 76031
CHU Toulouse
Toulouse, France, 31059
CHU tours
Tours, France, 37044
Sponsors and Collaborators
University Hospital, Bordeaux
Layout table for investigator information
Principal Investigator: Stéphanie Bui, Dr University Hospital Bordeaux, France
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: University Hospital, Bordeaux Identifier: NCT01344512    
Other Study ID Numbers: CHUBX 2010/36
First Posted: April 29, 2011    Key Record Dates
Last Update Posted: March 18, 2015
Last Verified: March 2015
Keywords provided by University Hospital, Bordeaux:
Additional relevant MeSH terms:
Layout table for MeSH terms
Anti-Bacterial Agents
Anti-Infective Agents
Topoisomerase II Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Cytochrome P-450 CYP1A2 Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Antifungal Agents
14-alpha Demethylase Inhibitors
Steroid Synthesis Inhibitors
Hormone Antagonists
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Cytochrome P-450 CYP3A Inhibitors